Ischemic Stroke Clinical Trial
Official title:
Prospective Multicenter Registry for Acute Ischemic Stroke Patients With Standard Reperfusion Therapy
Use of intravenous(IV) thrombolysis and intra-arterial(IA) recanalization treatment has been
rapidly increasing, However, despite of the treatment, recanalization rates are 22.6 - 70%
and only 30-50% of patients show meaningful clinical improvements. Mechanisms of futile
recanalization may include 1) large ischemic core, 2) poor collateral, and 3) presence of
comorbidity. In this regards, developing selection criteria using acute stroke imaging and
comorbidity is warranted.
The investigators will recruit the consecutive acute stroke patients who received IV
thrombolysis and/or IA recanalization treatment. This study will perform with prospective
design to develop CT-based clot, core and collateral scores and a comorbidity index for
selecting stroke patients who are at high risks by the treatment. The investigators will
firstly establish the CT-based scores and comorbidity index using a pre-existing cohort
database. Using these CT-based and comorbidity index, the investigators will validate them in
a multi-center prospectively cohort.
1)Full design
1. The study proceeds with a parallel design of retrospective and prospective research.
2. As in the retrospective study, this study aims to establish the ideal screening criteria
and to verify the efficacy of the thrombolytic procedure by using the relevant image
information, clinical information, and the history of the subjects.
3. This study is an observational study, and there is no intervention for the study.
2) retrospective design
1. Retrospective study was conducted as a multi-center retrospective cohort and intravenous
thrombolysis and intraarterial thrombus according to the guidelines for stroke among
patients who were admitted to neurology with stroke from January 1, 2012 to December 31,
2015 of participating hospitals. Patients who underwent surgical removal.
2. The retrospective study was performed after 3 months F / U and 6 months after confirming
the medical history and clinical information taken before the thrombolysis and the
accompanying disease history. Check whether or not.
3. We will establish the most ideal screening criteria and verify the efficacy of
predicting the prognosis after thrombolysis using the relevant imaging information,
clinical information and the accompanying disease history.
4. All data are collected using e-CRF, and CT angiography images of subjects are anonymized
and sent to the host institution. The lead institution quantifies the clinical
information, including CT angiographic indicators and accompanying diseases, in the
dark.
5. Interim analysis will be conducted once when the retrospective study is completed.
3) prospective design
1. A prospective study is a multicenter prospective observational study, in which
intravenous thrombolysis and arteries were already followed in accordance with
guidelines for stroke among patients who were admitted to neurology after a stroke on
November 1, 2016 (based on hospitalization date). Patients who have undergone internal
thrombectomy
2. Obtain a written consent form from a study subject who meets the selection / exclusion
criteria (see How to Obtain a Study Participation Consent Form), and collect the medical
data including the accompanying diseases of the study subject and images taken before
thrombosis (removal) treatment. do.
3. In the same way as retrospective study, confirm and confirm the image and clinical
information and the accompanying disease history of the study subjects and confirm the
survival after 3 months F / U and 6 months.
4. The observation period in the study is expected to take about 6 months (intravenous
thrombolytic therapy and intraarterial reopening therapy, mRS indicator at 3 months
after discharge and stroke, and survival at 6 months after stroke).
5. All data are collected using eCRF, and CT angiography images of subjects are anonymized
and sent to the host institution. The lead institution quantifies CT angiography and
associated disease indicators with blinded clinical information.
6. Screening (time of hospitalization due to stroke) Patients who had cerebrovascular
pretreatment prior to intravenous thrombolysis and were able to identify comorbidities.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A |